10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-10-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/864 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849773613942571008 |
|---|---|
| author | I. V. Kolyadina |
| author_facet | I. V. Kolyadina |
| author_sort | I. V. Kolyadina |
| collection | DOAJ |
| description | The article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the antitumor activity displayed by the drug. Among those presented, there are significant retrospective studies evaluating the role of eribulin chemotherapy in late and early advanced breast cancer treatment lines, as well as an analysis of surveys aimed to evaluate the efficacy of the drug in various clinical settings (for visceral metastases, brain lesion, and in elderly patients). This article reflects the main results of Russian population analyses evaluating the efficacy and safety of eribulin chemotherapy in routine clinical practice. |
| format | Article |
| id | doaj-art-3ea179a9dae8445e87cbc7f2168f9c46 |
| institution | DOAJ |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2021-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-3ea179a9dae8445e87cbc7f2168f9c462025-08-20T03:01:59ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272021-10-01173596810.17650/1994-4098-2021-17-3-59-6869910 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practiceI. V. Kolyadina0Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia; V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaThe article reviews studies evaluating the efficacy and safety of eribulin chemotherapy in patients with HER2-negative advanced breast cancer. It analyzes the results derived from large randomized studies, highlights the main advantages peculiar to eribulin, and describes the key mechanisms of the antitumor activity displayed by the drug. Among those presented, there are significant retrospective studies evaluating the role of eribulin chemotherapy in late and early advanced breast cancer treatment lines, as well as an analysis of surveys aimed to evaluate the efficacy of the drug in various clinical settings (for visceral metastases, brain lesion, and in elderly patients). This article reflects the main results of Russian population analyses evaluating the efficacy and safety of eribulin chemotherapy in routine clinical practice.https://ojrs.abvpress.ru/ojrs/article/view/864metastatic breast cancerlate-line chemotherapyearly-line chemotherapyeribulinvisceral metastasesbrain metastaseschemotherapy in elderly patientsrussian experience of using eribulineribulin introduced after cdk4/6 inhibitors |
| spellingShingle | I. V. Kolyadina 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice Опухоли женской репродуктивной системы metastatic breast cancer late-line chemotherapy early-line chemotherapy eribulin visceral metastases brain metastases chemotherapy in elderly patients russian experience of using eribulin eribulin introduced after cdk4/6 inhibitors |
| title | 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice |
| title_full | 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice |
| title_fullStr | 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice |
| title_full_unstemmed | 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice |
| title_short | 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice |
| title_sort | 10 years of success achieved by eribulin while treating her2 negative mbc from randomized studies to routine practice |
| topic | metastatic breast cancer late-line chemotherapy early-line chemotherapy eribulin visceral metastases brain metastases chemotherapy in elderly patients russian experience of using eribulin eribulin introduced after cdk4/6 inhibitors |
| url | https://ojrs.abvpress.ru/ojrs/article/view/864 |
| work_keys_str_mv | AT ivkolyadina 10yearsofsuccessachievedbyeribulinwhiletreatingher2negativembcfromrandomizedstudiestoroutinepractice |